HK1205500A1 - Kinase inhibitors for the treatment of cancer - Google Patents
Kinase inhibitors for the treatment of cancerInfo
- Publication number
- HK1205500A1 HK1205500A1 HK15105896.7A HK15105896A HK1205500A1 HK 1205500 A1 HK1205500 A1 HK 1205500A1 HK 15105896 A HK15105896 A HK 15105896A HK 1205500 A1 HK1205500 A1 HK 1205500A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- treatment
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012901199A AU2012901199A0 (en) | 2012-03-23 | Kinase inhibitors for the Treatment of Cancer | |
PCT/AU2013/000290 WO2013138863A1 (en) | 2012-03-23 | 2013-03-22 | Kinase inhibitors for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1205500A1 true HK1205500A1 (en) | 2015-12-18 |
Family
ID=49221707
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112097.9A HK1223832A1 (zh) | 2012-03-23 | 2015-06-19 | 用於癌症治療的激酶抑制劑 |
HK15105896.7A HK1205500A1 (en) | 2012-03-23 | 2015-06-19 | Kinase inhibitors for the treatment of cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112097.9A HK1223832A1 (zh) | 2012-03-23 | 2015-06-19 | 用於癌症治療的激酶抑制劑 |
Country Status (12)
Country | Link |
---|---|
US (2) | US9308193B2 (xx) |
EP (2) | EP3061451B1 (xx) |
JP (2) | JP6165231B2 (xx) |
KR (1) | KR102055176B1 (xx) |
CN (2) | CN105534969B (xx) |
AU (2) | AU2013234869B2 (xx) |
CA (1) | CA2868120C (xx) |
ES (2) | ES2732229T3 (xx) |
HK (2) | HK1223832A1 (xx) |
NZ (2) | NZ714625A (xx) |
PL (1) | PL2817286T3 (xx) |
WO (1) | WO2013138863A1 (xx) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014022879A1 (en) | 2012-08-06 | 2014-02-13 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of mtor pathway related diseases |
ES2940890T3 (es) * | 2013-11-01 | 2023-05-12 | Pitney Pharmaceuticals Pty Ltd | Combinaciones farmacéuticas para el tratamiento del cáncer |
JPWO2021177334A1 (xx) * | 2020-03-04 | 2021-09-10 | ||
EP4149454A1 (en) * | 2020-05-11 | 2023-03-22 | Pitney Pharmaceuticals Pty Limited | Use of aminoacetonitrile compounds for the treatment of infection and disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4584305A (en) * | 1972-08-17 | 1986-04-22 | Janssen Pharmaceutica N.V. | Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
AR036054A1 (es) * | 2001-06-15 | 2004-08-04 | Novartis Ag | Uso de compuestos de aminoacetonitrilo para el control de plagas, una composicion y un proceso para dicho control y una composicion farmaceutica contra parasitos |
GB0402677D0 (en) * | 2003-11-06 | 2004-03-10 | Novartis Ag | Organic compounds |
AR049391A1 (es) * | 2004-06-10 | 2006-07-26 | Novartis Ag | Derivados de aminoacetonitrilo y su uso para controlar parasitos en animales de sangre caliente |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
CN102127074A (zh) * | 2010-12-17 | 2011-07-20 | 中国药科大学 | 6-氨磺酰基取代-β-咔啉-1-酮类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
-
2013
- 2013-03-22 WO PCT/AU2013/000290 patent/WO2013138863A1/en active Application Filing
- 2013-03-22 NZ NZ714625A patent/NZ714625A/en not_active IP Right Cessation
- 2013-03-22 PL PL13764613T patent/PL2817286T3/pl unknown
- 2013-03-22 CA CA2868120A patent/CA2868120C/en active Active
- 2013-03-22 AU AU2013234869A patent/AU2013234869B2/en active Active
- 2013-03-22 CN CN201610041111.6A patent/CN105534969B/zh not_active Expired - Fee Related
- 2013-03-22 JP JP2015500717A patent/JP6165231B2/ja active Active
- 2013-03-22 ES ES16162192T patent/ES2732229T3/es active Active
- 2013-03-22 EP EP16162192.5A patent/EP3061451B1/en active Active
- 2013-03-22 CN CN201380024851.3A patent/CN104364232B/zh active Active
- 2013-03-22 US US14/387,270 patent/US9308193B2/en active Active
- 2013-03-22 NZ NZ630807A patent/NZ630807A/en unknown
- 2013-03-22 EP EP13764613.9A patent/EP2817286B1/en active Active
- 2013-03-22 KR KR1020147029526A patent/KR102055176B1/ko active IP Right Grant
- 2013-03-22 ES ES13764613.9T patent/ES2685612T3/es active Active
-
2015
- 2015-06-19 HK HK16112097.9A patent/HK1223832A1/zh unknown
- 2015-06-19 HK HK15105896.7A patent/HK1205500A1/xx unknown
-
2016
- 2016-03-01 US US15/057,628 patent/US20160220527A1/en not_active Abandoned
- 2016-06-27 AU AU2016204389A patent/AU2016204389B2/en not_active Ceased
-
2017
- 2017-02-28 JP JP2017036116A patent/JP6483736B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2013234869A1 (en) | 2014-10-02 |
JP6483736B2 (ja) | 2019-03-13 |
EP3061451A1 (en) | 2016-08-31 |
US9308193B2 (en) | 2016-04-12 |
CN104364232A (zh) | 2015-02-18 |
PL2817286T3 (pl) | 2018-11-30 |
JP6165231B2 (ja) | 2017-07-19 |
ES2732229T3 (es) | 2019-11-21 |
KR102055176B1 (ko) | 2019-12-12 |
CN105534969A (zh) | 2016-05-04 |
KR20140145604A (ko) | 2014-12-23 |
JP2017125041A (ja) | 2017-07-20 |
AU2016204389B2 (en) | 2018-01-25 |
HK1223832A1 (zh) | 2017-08-11 |
US20150051290A1 (en) | 2015-02-19 |
US20160220527A1 (en) | 2016-08-04 |
NZ714625A (en) | 2017-02-24 |
CN104364232B (zh) | 2017-05-31 |
JP2015510898A (ja) | 2015-04-13 |
WO2013138863A1 (en) | 2013-09-26 |
ES2685612T3 (es) | 2018-10-10 |
AU2013234869B2 (en) | 2016-06-30 |
EP2817286A4 (en) | 2015-09-02 |
AU2016204389A1 (en) | 2016-07-14 |
EP2817286A1 (en) | 2014-12-31 |
CA2868120C (en) | 2019-02-19 |
NZ630807A (en) | 2016-04-29 |
EP2817286B1 (en) | 2018-06-06 |
EP3061451B1 (en) | 2019-05-08 |
CN105534969B (zh) | 2019-04-05 |
CA2868120A1 (en) | 2013-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
HK1243919A1 (zh) | 利用tor激酶抑制劑治療癌症 | |
HRP20171474T1 (hr) | Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka | |
HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
PT3418281T (pt) | Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro | |
HK1210174A1 (en) | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases | |
EP3019491A4 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
HK1206338A1 (en) | Pyrimidine compounds for the treatment of cancer | |
HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
EP2925752A4 (en) | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT | |
HK1205500A1 (en) | Kinase inhibitors for the treatment of cancer | |
EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors | |
AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer | |
HK1200094A1 (en) | Use of immunomodulators for the treatment of cancer |